E-Book | December 13, 2024

Artificial Intelligence Regulation

Source: Citeline
GettyImages-1474595785 AI

To make the best use of artificial intelligence (AI), drug sponsors need to understand where health authorities are drawing the lines. The EMA has finalized a reflection paper that underscores a principle-based framework for AI integration across the medicinal product lifecycle. They've also advanced AI tools for regulatory assessors. In parallel, the FDA is navigating AI policy development through a multi-faceted approach, creating specialized groups and an AI Council to address AI’s integration into drug development. As our understanding and use of AI continually shifts one rule of thumb remains constant: The closer AI is to patient care, the more scrutiny it will receive.

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader